Lightstone Ventures is a leading global venture capital firm.
Business Model:
Revenue: $14.6M
Employees: 51-200
Address: 485 Ramona St
City: Palo Alto
State: CA
Zip: 94301
Country: US
Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space.
Contact Phone:
+16503883676
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2019 | Cyteir Therapeutics | Series B | 40.2M |
1/2017 | Allay Therapeutics | Series A | 7M |
5/2019 | Locanabio | Series A | 55M |
7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
9/2020 | Willow | Series C | 0 |
4/2014 | Earlens | Series B | 40M |
10/2017 | Claret Medical | Series C | 0 |
3/2023 | Relievant Medsystems | Series G | 0 |
4/2016 | FIRE1 | Series B | 7.5M |
2/2016 | Cala Health | Series B | 0 |
3/2017 | ALX Oncology | Convertible Note | 25M |
6/2018 | Relievant Medsystems | Series E | 58M |
10/2017 | Gemini Therapeutics | Series A | 42.5M |
9/2019 | Bold Penguin | Series B | 32M |
4/2020 | Cerevance | Series B | 65M |
4/2021 | WayCool | Series C | 0 |
1/2021 | Ligature Therapeutics | Seed Round | 0 |
3/2015 | Nimbus Apollo | Series B | 43M |
5/2017 | Cerevance | Series A | 5M |
3/2016 | Tizona Therapeutics | Series B | 43M |
6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
12/2021 | Choiceform | Venture Round | 30M |
12/2020 | Locanabio | Series B | 0 |
3/2023 | Shoulder Innovations | Series D | 0 |
10/2016 | Carrick Therapeutics | Series A | 95M |
3/2018 | Cyteir Therapeutics | Series B | 29M |
1/2023 | Volta Medical | Series B | 0 |
9/2017 | Disarm Therapeutics | Series A | 30M |
2/2019 | Nuvaira | Equity | 79M |
11/2013 | Astria Therapeutics | Series B | 32.4M |
2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
1/2019 | Allay Therapeutics | Series B | 25M |
4/2016 | Gemini Therapeutics | Seed Round | 2M |
8/2014 | Claret Medical | Series B | 0 |
8/2021 | Vigil Neuroscience | Series B | 0 |
3/2023 | FIRE1 | Venture Round | 0 |
2/2020 | ALX Oncology | Series C | 105M |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
10/2018 | Earlens | Series D | 0 |
3/2015 | ALX Oncology | Series A | 36M |
12/2020 | Tallac Therapeutics | Series A | 62M |
11/2020 | Shoulder Innovations | Venture Round | 0 |
1/2014 | FIRE1 | Series A | - |
10/2020 | Relievant Medsystems | Venture Round | 0 |
10/2015 | Elcelyx Therapeutics | Series E | 0 |
2/2023 | Cerevance | Series B | 0 |
12/2016 | Cerevance | Series A | 21.5M |
12/2019 | Willow | Series C | 20M |
6/2017 | Earlens | Series C | 0 |
12/2020 | Atsena Therapeutics | Series A | 0 |
6/2018 | Nimbus Therapeutics | Series B | 65M |
5/2018 | Medisix Therapeutics | Series A | 20M |
11/2020 | Catamaran Bio | Series A | 0 |
6/2016 | Earlens | Series C | 0 |
2/2021 | Cyteir Therapeutics | Series C | 0 |
5/2019 | Cala Health | Series C | 0 |
3/2015 | Nimbus Therapeutics | Series B | 43M |
9/2014 | Flex Pharma | Venture Round | 0 |
1/2022 | ProVerum Medical | Series A | 0 |
1/2018 | FIRE1 | Series C | 49.6M |
4/2021 | Alchemab Therapeutics | Series A | 82.7M |
12/2022 | Carrick Therapeutics | Series C | 0 |
1/2022 | ProVerum Medical | Series A | 0 |
12/2021 | Choiceform | Venture Round | 0 |
8/2021 | Vigil Neuroscience | Series B | 0 |
4/2021 | Alchemab Therapeutics | Series A | 0 |
4/2021 | WayCool | Series C | 0 |
2/2021 | Cyteir Therapeutics | Series C | 0 |
2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
1/2021 | Ligature Therapeutics | Seed Round | 0 |
12/2020 | Atsena Therapeutics | Series A | 0 |
12/2020 | Locanabio | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|